PD-L1 INHIBITOR PEMBROLIZUMAB – FOR FIRST LINE ADVANCED NON-SMALL CELL LUNG CANCER THERAPY

Abstract

Pembrolizumab is first and the only programmed death protein 1 (PD-1) inhibitor, approved for the first-line advanced ormetastatic non-small cell lung cancer (NSCLC)monotherapy,when tumor express high programmed death ligand 1 (PD-L1) level (≥50 proc.), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.Approval of pembrolizumab efficacy and safety is based on a series of clinical trials, inwhich pembrolizumab
significantly prolonged overall survival and progression free survival rates compared with platinum-based chemotherapy for NSCLC patientswith high PD-L1 expression, pembrolizumab also and was relatedwith less adverse events. It is safe and effective immunotherapy drug for advanced or metastatic NSCLC treatment with high PD-L1 expression.